Myriad Genetics Inc vs. Intellia Therapeutics, Inc
Myriad Genetics Inc (MYGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| MYGN | NTLA | |
|---|---|---|
| Market Cap | $305.12 million | $1.72 billion |
| Revenue (TTM) | $806.60 million | $59.51 million |
| Net Income (TTM) | $-112,600,000 | $-399,975,000 |
MYGN leads on 2 of 3 size & scale factors.
Valuation
| MYGN | NTLA | |
|---|---|---|
| Price / Book | 1.00 | 2.36 |
| Price / Sales | 0.38 | 28.87 |
MYGN leads on 2 of 2 valuation factors.
Profitability
| MYGN | NTLA | |
|---|---|---|
| Net Margin | -13.96% | -672.16% |
| Return on Equity | -37.05% | -54.96% |
MYGN leads on 2 of 2 profitability factors.
Risk & Sentiment
| MYGN | NTLA | |
|---|---|---|
| Short Interest | 13.76% | 2.43% |
NTLA leads on 1 of 1 risk & sentiment factors.
Dig deeper: MYGN overview, MYGN financials, NTLA overview, NTLA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.